NCT06021197View on ClinicalTrials.gov

NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 12, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

March 31, 2028

Conditions
Schizophrenia
Interventions
DRUG

NMDAE

Use of an NMDA enhancer for the treatment of CIAS

DRUG

Placebo Cap

Use of placebo as a comparator

Trial Locations (1)

Unknown

RECRUITING

Department of Psychiatry, China Medical University Hospital, Taichung

All Listed Sponsors
collaborator

National Science and Technology Council, Taiwan

OTHER_GOV

lead

China Medical University Hospital

OTHER